Total hemoglobin changes in the breast tumors volume of patients undergoing neoadjuvant chemotherapy: a longitudinal analysis

Mirella L. Altoé; Alessandro Marone; Hyun K. Kim; Hua Guo; Hanina Hibshoosh; Mariella Tejada; Katherine D. Crew; Melissa K. Accordino; Meghna S. Trivedi; Kevin Kalinsky; Dawn L. Hershman; Andreas H. Hielscher

doi:10.1117/12.2583101

5 March 2021 Total hemoglobin changes in the breast tumors volume of patients undergoing neoadjuvant chemotherapy: a longitudinal analysis

Mirella L. Altoé, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Kevin Kalinsky, Dawn L. Hershman, Andreas H. Hielscher

Author Affiliations +

Proceedings Volume 11639, Optical Tomography and Spectroscopy of Tissue XIV; 1163909 (2021) https://doi.org/10.1117/12.2583101
Event: SPIE BiOS, 2021, Online Only

Abstract

Optical imaging techniques have emerged as a possible alternative to predict pathological complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Our team developed a so-called diffuse optical tomographic breast imaging system (DOTBIS) which does not require the use of contrast agents or compression and enables imaging of the whole breast volume using low intensity near infrared light capable to measure tissue concentration of total hemoglobin (ctTHb). In this retrospective study, we evaluated 55 stage II-III BC patients in the neoadjuvant setting who received weekly paclitaxel x 12, followed by dose-dense adriamycin/cyclophosphamide every 2 weeks x 4. DOTBIS images were acquired from the patient whole breast volume at 6 different time points: at baseline (TP0); two weeks after the first taxane infusion (TP1); after four infusions of taxane (TP2); at the end of the taxane regimen and before starting AC cycle (TP3); after two AC infusions (TP4); and at the end of NAC and before surgery (TP5). In order to evaluate whether pCR status influences the change of ctTHb over time, we designed a multilevel mixed-effect model. pCR was defined as no invasive tumor cells from the breast and axillary tissue at surgery (ypT0 ypN0). Changes in ctTHb levels compared to baseline (TP0) values were statistically significant different between pCR (n = 20) and non-pCR (n=35) at all time points except at TP1 and at the end of the taxane cycle (TP3).

Conference Presentation

Citation Download Citation

Mirella L. Altoé, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Kevin Kalinsky, Dawn L. Hershman, and Andreas H. Hielscher "Total hemoglobin changes in the breast tumors volume of patients undergoing neoadjuvant chemotherapy: a longitudinal analysis", Proc. SPIE 11639, Optical Tomography and Spectroscopy of Tissue XIV, 1163909 (5 March 2021); https://doi.org/10.1117/12.2583101

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available